Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 7
1965 36
1966 215
1967 428
1968 543
1969 687
1970 712
1971 776
1972 878
1973 1033
1974 1104
1975 1110
1976 1296
1977 1237
1978 1168
1979 1266
1980 1365
1981 1362
1982 1461
1983 1489
1984 1560
1985 1531
1986 1347
1987 1344
1988 1317
1989 1394
1990 1223
1991 1175
1992 1018
1993 913
1994 817
1995 768
1996 686
1997 631
1998 604
1999 612
2000 580
2001 447
2002 473
2003 501
2004 473
2005 462
2006 474
2007 465
2008 456
2009 493
2010 570
2011 631
2012 598
2013 630
2014 647
2015 661
2016 531
2017 580
2018 580
2019 558
2020 596
2021 577
2022 502
2023 220

Text availability

Article attribute

Article type

Publication date

Search Results

46,422 results

Results by year

Filters applied: . Clear all
Page 1
Propranolol.
Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H. Al-Majed AA, et al. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338. doi: 10.1016/bs.podrm.2017.02.006. Epub 2017 Apr 6. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431779
Propranolol is a noncardioselective beta-blocker. It is reported to have membrane-stabilizing properties, but it does not own intrinsic sympathomimetic activity. Propranolol hydrochloride is used to control hypertension, pheochromocytoma, myocardial infarction, card …
Propranolol is a noncardioselective beta-blocker. It is reported to have membrane-stabilizing properties, but it does not own intrins …
β-blocker therapy for infantile hemangioma.
Koh SP, Leadbitter P, Smithers F, Tan ST. Koh SP, et al. Expert Rev Clin Pharmacol. 2020 Aug;13(8):899-915. doi: 10.1080/17512433.2020.1788938. Expert Rev Clin Pharmacol. 2020. PMID: 32662682 Review.
AREAS COVERED: The demonstration of a hemogenic endothelium origin of IH, with a neural crest phenotype and multi-lineage differentiation capacity, regulated by the renin-angiotensin system, underscores its programmed biologic behavior and accelerated involution induced by pro …
AREAS COVERED: The demonstration of a hemogenic endothelium origin of IH, with a neural crest phenotype and multi-lineage differentiation ca …
Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta.
Lee JC, Modiri O, England RW, Shawber CJ, Wu JK. Lee JC, et al. Plast Reconstr Surg. 2021 Apr 1;147(4):875-885. doi: 10.1097/PRS.0000000000007699. Plast Reconstr Surg. 2021. PMID: 33776033
BACKGROUND: Propranolol, a nonselective beta-adrenergic receptor antagonist, is approved by the U.S. ...Parents wary of long-term use and side effects consult plastic surgeons on surgical options or as a second opinion. Understanding the mechanism(s) of actio …
BACKGROUND: Propranolol, a nonselective beta-adrenergic receptor antagonist, is approved by the U.S. ...Parents wary of long-t …
Propranolol.
[No authors listed] [No authors listed] Br Med J. 1966 Nov 26;2(5525):1311-2. Br Med J. 1966. PMID: 5924821 Free PMC article. No abstract available.
Propranolol.
[No authors listed] [No authors listed] Lancet. 1967 Apr 29;1(7496):939-40. Lancet. 1967. PMID: 4164409 No abstract available.
Can propranolol prevent progression of melanoma?
Kao J, Luu B. Kao J, et al. JAAPA. 2019 Jun;32(6):1-5. doi: 10.1097/01.JAA.0000558241.84003.91. JAAPA. 2019. PMID: 31136408 Review.
Studies have demonstrated the potential anticarcinogenic effects of antihypertensive agents, specifically beta-blockers, in patients with prostate cancer, breast cancer, and lately cutaneous malignant melanoma. This article explores the empirical clinical evidence of propranol …
Studies have demonstrated the potential anticarcinogenic effects of antihypertensive agents, specifically beta-blockers, in patients with pr …
Propranolol in hypertension.
Ahlquist RP. Ahlquist RP. J Clin Pharmacol. 1977 Feb-Mar;17(2-3):93-4. doi: 10.1002/j.1552-4604.1977.tb04594.x. J Clin Pharmacol. 1977. PMID: 13091 No abstract available.
Methods and approaches for determination and enantioseparation of (RS)-propranolol.
Batra S, Bhushan R. Batra S, et al. Biomed Chromatogr. 2019 Jan;33(1):e4370. doi: 10.1002/bmc.4370. Epub 2018 Sep 30. Biomed Chromatogr. 2019. PMID: 30121955 Review.
Propranolol, a beta-adrenergic receptor antagonist, is a chiral compound that is marketed as a racemate, but only the (S)-(-)-enantiomer is responsible for the beta-adrenoceptor blocking activity. Different chromatographic methods have been applied for separation an …
Propranolol, a beta-adrenergic receptor antagonist, is a chiral compound that is marketed as a racemate, but only the (S)-(-)- …
Once-daily propranolol.
Dunn JM, Groth PE, DeSimone A. Dunn JM, et al. Lancet. 1985 Nov 23;2(8465):1183. doi: 10.1016/s0140-6736(85)92701-1. Lancet. 1985. PMID: 2865633 Clinical Trial. No abstract available.
Pharmacokinetic drug interactions with propranolol.
Wood AJ, Feely J. Wood AJ, et al. Clin Pharmacokinet. 1983 May-Jun;8(3):253-62. doi: 10.2165/00003088-198308030-00004. Clin Pharmacokinet. 1983. PMID: 6342901 Review.
Induction of propranolol's metabolism by halofenate, phenytoin, phenobarbitone, rifampicin and alcohol have all been implicated in altering propranolol clearance, while inhibition of hepatic drug metabolising enzymes by chlorpromazine and cimetidine appear to …
Induction of propranolol's metabolism by halofenate, phenytoin, phenobarbitone, rifampicin and alcohol have all been implicate …
46,422 results
You have reached the last available page of results. Please see the User Guide for more information.